Skip to main content

Noria is a radiotherapy company developing targeted therapeutic and imaging radiopharmaceuticals (alpha-emitting) for use in oncology. The lead oncology therapeutic candidate is PSMA-PK-Rx. This product will be used for the treatment of metastatic castrate resistant prostate cancers (mCRPC). This therapeutic can be ‘paired’ with their PSMA imaging agent PSMA-PK-Dx to create a unique theranostic alternative for men suffering with prostate cancer. The company’s pipeline includes SOMA-PK-Rx and SOMA-PK-Dx another theranostic pairing for the treatment and imaging of neuroendocrine cancers, respectively.